What is Ovagen ?
Ovagen is a synthetic tripeptide with the sequence Glu-Asp-Leu (EDL), developed by Vladimir Kh. Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The compound is sold in Russia as a biologically active food supplement (BAFS) under the Cytogen / Garmonia commercial line. IMPORTANT framing: despite frequent marketing as a hepatoprotective or gastrointestinal bioregulator, every PubMed-indexed primary research paper on EDL studies kidney endpoints, not liver. The Khavinson-group publications document EDL effects on rat renal cell culture senescence markers (p16, p21, p53, SIRT-6), MMP-14 gene expression in kidney cells, and protective effects in rat models of cisplatin nephrotoxicity, gentamicin nephropathy, and ischemia-reperfusion kidney injury. The hepatoprotection claim circulating in commercial channels rests on a single table entry in a 2021 Khavinson review (PMID 34834147) citing a 2005 monograph (Khavinson and Malinin, Karger), not a primary experimental paper. The Khavinson liver tetrapeptide work is on KEDA (Livagen), a different compound. Six PubMed-indexed primary research papers on EDL exist, all rat or in vitro studies, all from the Khavinson network. No human clinical trial, no human pharmacokinetic data, no FDA or EMA registration, no Russian pharmaceutical drug registration verified for the synthetic tripeptide.
















